Recombinant SARS-CoV-2 Spike S2 (ECD) His (C-Term) Protein
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-92990
Key Product Details
Source
Baculovirus
Tag
His (C-Term)
Conjugate
Unconjugated
Applications
SDS-PAGE
Product Specifications
Description
Recombinant SARS-CoV-2 Spike S2 ECD Protein is produced by Baculovirus-Insect Cells expression system. The target protein is expressed with sequence (Ser686-Pro1213) of SARS-CoV-2 Spike S2 ECD (Accession #YP_009724390.1) fused with a His tag at the C-terminus.
Store the lyophilized protein at -20 degrees C to -80 degrees C for long term. After reconstitution, the protein solution is stable at -20 degrees C for 3 months, at 2-8 degrees C for up to 1 week.
Store the lyophilized protein at -20 degrees C to -80 degrees C for long term. After reconstitution, the protein solution is stable at -20 degrees C for 3 months, at 2-8 degrees C for up to 1 week.
Purity
>90%, by SDS-PAGE
Endotoxin Level
< 1.0 EU/ug of the protein by LAL method.
Predicted Molecular Mass
58 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Protein / Peptide Type
Recombinant Protein
Scientific Data Images for Recombinant SARS-CoV-2 Spike S2 (ECD) His (C-Term) Protein
SDS-PAGE: Recombinant SARS-CoV-2 Spike S2 (ECD) His (C-Term) Protein [NBP2-92990]
SDS-Page: Recombinant SARS-CoV-2 Spike S2 (ECD) His (C-Term) Protein [NBP2-92990] - Recombinant Virus SARS-CoV-2 Spike S2 ECD Protein with His tag was determined by SDS-PAGE with Coomassie Blue, showing a band at 70 kDa.Formulation, Preparation and Storage
NBP2-92990
Formulation | Lyophilized from a 0.22 um filtered solution of sterile 20 mM PBS, 300 mM NaCl, pH 7.0 |
Preservative | No Preservative |
Concentration | Lyoph |
Reconstitution | Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. |
Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Store at -20 to -70C. Avoid freeze-thaw cycles. |
Background: Spike S2 Subunit
Given the critical role of the spike protein RBD in the interaction with the ACE2 receptor and viral entry, a number of neutralizing antibodies against the RBD have been developed as potential therapeutics for treating COVID-19 (3). These antibodies bind the RBD domain on the S1 subunit inhibiting the interaction with ACE2 (3). However, more studies need to be done as neutralizing antibodies can result in antibody-dependent enhancement, in which the viral entry and replication within the host cell is increased (4). One potential way to combat antibody-dependent enhancement is the use of nanobodies (4). Furthermore, there are currently several vaccine strategies that are in clinical trials, or recently federally approved, that utilize the spike protein in different forms (e.g. full length, S1 RBD, RBD-Fc, N-terminal) for protecting against SARS-CoV-2 infection (4,5). These vaccine strategies include DNA vaccines, viral vector-based vaccines, RNA vaccines, and subunit vaccines (4,5).
References
1. Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2020-206658
2. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.
3. Ho M. (2020). Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antibody Therapeutics. https://doi.org/10.1093/abt/tbaa009
4. Samrat, S. K., Tharappel, A. M., Li, Z., & Li, H. (2020). Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development. Virus Research. https://doi.org/10.1016/j.virusres.2020.198141
5. Sternberg, A., & Naujokat, C. (2020). Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sciences. https://doi.org/10.1016/j.lfs.2020.118056
Long Name
Spike Protein, S2 Subunit
Alternate Names
COVID-19, S2 protein, SARS-CoV-2, SARS-CoV-2 Spike, Spike glycoprotein Subunit 2, spike protein, Spike protein S2, structural protein, surface glycoprotein
Gene Symbol
S
Additional Spike S2 Subunit Products
Product Documents for Recombinant SARS-CoV-2 Spike S2 (ECD) His (C-Term) Protein
Product Specific Notices for Recombinant SARS-CoV-2 Spike S2 (ECD) His (C-Term) Protein
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...